102 related articles for article (PubMed ID: 33886689)
1. Correction: Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
PLoS One; 2021; 16(4):e0250863. PubMed ID: 33886689
[TBL] [Abstract][Full Text] [Related]
2. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
[TBL] [Abstract][Full Text] [Related]
3. The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries.
Sicuri E; Yaya Bocoum F; Nonvignon J; Alonso S; Fakih B; Bonsu G; Kariuki S; Leeuwenkamp O; Munguambe K; Mrisho M; Were V; Sauboin C
MDM Policy Pract; 2019; 4(2):2381468319896280. PubMed ID: 31903424
[No Abstract] [Full Text] [Related]
4. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
5. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
Vandoolaeghe P; Schuerman L
Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
[TBL] [Abstract][Full Text] [Related]
6. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study.
Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
Malar J; 2015 Dec; 14():524. PubMed ID: 26702637
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
Agnandji ST; Fernandes JF; Bache EB; Ramharter M
Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
[TBL] [Abstract][Full Text] [Related]
8. Decrease in circulating CD25(hi)Foxp3(+) regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.
Parsons E; Epstein J; Sedegah M; Villasante E; Stewart A
Vaccine; 2016 Aug; 34(38):4618-4625. PubMed ID: 27443592
[TBL] [Abstract][Full Text] [Related]
9. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
Vandoolaeghe P; Schuerman L
Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
[TBL] [Abstract][Full Text] [Related]
10. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
[TBL] [Abstract][Full Text] [Related]
11. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
[TBL] [Abstract][Full Text] [Related]
12. RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials.
van den Berg M; Ogutu B; Sewankambo NK; Biller-Andorno N; Tanner M
Trials; 2019 May; 20(1):316. PubMed ID: 31151473
[TBL] [Abstract][Full Text] [Related]
13. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure.
Kurtovic L; Agius PA; Feng G; Drew DR; Ubillos I; Sacarlal J; Aponte JJ; Fowkes FJI; Dobaño C; Beeson JG
BMC Med; 2019 Feb; 17(1):45. PubMed ID: 30798787
[TBL] [Abstract][Full Text] [Related]
14. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
von Seidlein L
Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
[TBL] [Abstract][Full Text] [Related]
15. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
[TBL] [Abstract][Full Text] [Related]
16. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
Hogan AB; Winskill P; Ghani AC
PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
[TBL] [Abstract][Full Text] [Related]
18. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review.
Dimala CA; Kika BT; Kadia BM; Blencowe H
PLoS One; 2018; 13(12):e0209744. PubMed ID: 30596732
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
20. Differential Patterns of IgG Subclass Responses to
Dobaño C; Santano R; Vidal M; Jiménez A; Jairoce C; Ubillos I; Dosoo D; Aguilar R; Williams NA; Díez-Padrisa N; Ayestaran A; Valim C; Asante KP; Owusu-Agyei S; Lanar D; Chauhan V; Chitnis C; Dutta S; Angov E; Gamain B; Coppel RL; Beeson JG; Reiling L; Gaur D; Cavanagh D; Gyan B; Nhabomba AJ; Campo JJ; Moncunill G
Front Immunol; 2019; 10():439. PubMed ID: 30930896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
